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Introduction {#jdi12024-sec-0001}
============

Fulminant type 1 diabetes is an independent subtype within type 1 diabetes that was discovered and clinically characterized in Japan. The following findings are clinical characteristics observed in this subtype: markedly rapid onset of hyperglycemia with ketoacidosis, near normal glycated hemoglobin (HbA~1c~) levels despite remarkable hyperglycemia, negative status of islet‐related autoantibodies, an absence of insulin secreting capacity even at disease onset and elevation of serum pancreatic enzyme levels[2](#jdi12024-bib-0002){ref-type="ref"}.

The Japan Diabetes Society (JDS) set up a research committee, carried out a nationwide survey and reported the detailed characteristics of this new clinical entity in 2004[3](#jdi12024-bib-0003 jdi12024-bib-0004){ref-type="ref"}. Based on that report, the society introduced two sets of criteria; one was for screening so that affected patients would not be missed, and the other was established for the diagnosis of the disease (Tables [1](#jdi12024-tbl-0001){ref-type="table-wrap"} and [2](#jdi12024-tbl-0002){ref-type="table-wrap"}). These criteria have now been widely used, not only in Japan, but also worldwide.

###### Criteria for screening of fulminant type 1 diabetes mellitus (2004)

  -------------------------------------------------------------------------------------
  1\) Ketosis or ketoacidosis within 1 week after the onset of hyperglycemic symptoms
  2\) Plasma glucose level ≥16.0 mmol/L (≥288 mg/dL) at first visit
  -------------------------------------------------------------------------------------
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###### Criteria for definite diagnosis of fulminant type 1 diabetes mellitus (2004)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Fulminant type 1 diabetes mellitus is confirmed when all the following three findings are present:
  1\) Occurrence of diabetic ketosis or ketoacidosis soon (approximately 7 days) after the onset of hyperglycemic symptoms (elevation of urinary and/or serum ketone bodies at first visit)
  2\) Plasma glucose level ≥16.0 mmol/L (≥288 mg/dL) and glycated hemoglobin level \<8.5% (Japan Diabetes Society value) at first visit
  3\) Urinary C‐peptide excretion \<10 μg/day or fasting serum C‐peptide level \<0.3 ng/mL (\<0.10 nmol/L) and \<0.5 ng/mL (\<0.17 nmol/L) after intravenous glucagon (or after meal) load at onset
  Other findings in fulminant type 1 diabetes mellitus:
  A\) Islet‐related autoantibodies, such as antibodies to glutamic acid decarboxylase, islet‐associated antigen 2 and insulin are undetectable in general
  B\) Duration of the disease before the start of insulin treatment can be 1--2 weeks
  C\) Elevation of serum pancreatic enzyme levels (amylase, lipase or elastase‐1) is observed in 98% of the patients
  D\) Flu‐like symptoms (fever, upper respiratory symptoms, etc.) or gastrointestinal symptoms (upper abdominal pain, nausea and/or vomiting, etc.) precede the disease onset in 70% of patients
  E\) The disease can occur during pregnancy or just after delivery
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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The Committee of the Japan Diabetes Society on the Research of Fulminant and Acute‐onset Type 1 Diabetes Mellitus started to re‐evaluate the criteria after the transition of HbA~1c~ from the JDS value to the National Glycohemoglobin Standardization Program (NGSP) value was made by the JDS in 2012[5](#jdi12024-bib-0005 jdi12024-bib-0006 jdi12024-bib-0007 jdi12024-bib-0008 jdi12024-bib-0009 jdi12024-bib-0010 jdi12024-bib-0011 jdi12024-bib-0012 jdi12024-bib-0013 jdi12024-bib-0014 jdi12024-bib-0015 jdi12024-bib-0016 jdi12024-bib-0017 jdi12024-bib-0018 jdi12024-bib-0019){ref-type="ref"}.

Methods {#jdi12024-sec-0002}
=======

Our re‐evaluation was carried out based on the records of 382 patients with newly‐diagnosed fulminant type 1 diabetes and those collected from other published findings[5](#jdi12024-bib-0005 jdi12024-bib-0006 jdi12024-bib-0007 jdi12024-bib-0008 jdi12024-bib-0009 jdi12024-bib-0010 jdi12024-bib-0011 jdi12024-bib-0012 jdi12024-bib-0013 jdi12024-bib-0014 jdi12024-bib-0015 jdi12024-bib-0016 jdi12024-bib-0017){ref-type="ref"}. The records had been submitted to the committee for the past 12 years. We also evaluated 122 patients with classical autoimmune type 1A diabetes from the nationwide survey carried out in 2004.

Results {#jdi12024-sec-0003}
=======

A histogram of the HbA~1c~ values of 382 patients with fulminant type 1 diabetes and 122 patients with classical type 1A diabetes are shown in Figure [1](#jdi12024-fig-0001){ref-type="fig"}. The candidate cut‐off value, and the sensitivity and specificity using each value are shown in Table [3](#jdi12024-tbl-0003){ref-type="table-wrap"}. The HbA~1c~ (NGSP) value was 6.8% on average in the 382 patients with fulminant type 1 diabetes, and was below 7.0% in 70.2% of those patients.

###### Candidate cut‐off values, and their sensitivity and specificity

  HbA~1c~ (NGSP)   HbA~1c~ (JDS)   Specificity   Sensitivity
  ---------------- --------------- ------------- -------------
  8.5              8.1             100.0         98.4
  8.6              8.2             99.2          99.2
  8.7              8.3             99.2          100.0
  8.8              8.4             99.2          100.0
  8.9              8.5             99.2          100.0
  9.0              8.6             97.5          100.0
  9.1              8.7             95.9          100.0

HbA~1c~, glycated hemoglobin; JDS, Japan Diabetes Society; NGSP, National Glycohemoglobin Standardization Program.
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![Glycated hemoglobin (HbA~1c~) concentrations at onset in (a) 382 patients with fulminant type 1 diabetes and (b) 122 patients with classical acute onset type 1A diabetes. JDS, Japan Diabetes Society.](jdi-3-536-g1){#jdi12024-fig-0001}

Discussion {#jdi12024-sec-0004}
==========

Based on these data, we decided to use 'HbA~1c~ \<8.7% (NGSP)' in the new diagnostic criteria (Table [4](#jdi12024-tbl-0004){ref-type="table-wrap"}). A simple conversion of HbA~1c~ (JDS) \<8.5% in the previous diagnostic criteria to the HbA~1c~ (NGSP) value resulted in HbA~1c~ (NGSP) \<8.9%. In this case, the sensitivity was 100%, and the specificity 97.5%. When we established the previous criteria for fulminant type 1 diabetes in 2004, we emphasized the prevention of a misdiagnosis that would directly result in the death of the patient. This meant that the sensitivity had to be 100%. In contrast, the presence of a low HbA~1c~ value despite a high blood glucose level at the same time indicates a rapid deterioration of the blood glucose level, which is the most important aspect of fulminant type 1 diabetes. The average value at the time of onset was 6.4% (JDS; = 6.8% \[NGSP\]). It is therefore reasonable to use a lower value of HbA~1c~ in the diagnostic criteria. In the present study, the cut‐off value of the HbA~1c~ was set as the minimum value to maintain the 100% sensitivity, which was 'HbA~1c~ \<8.7% (NGSP)'. This value was also the optimal value identified in the receiver operating characteristic curve analysis.

###### Criteria for definite diagnosis of fulminant type 1 diabetes mellitus (2012)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Fulminant type 1 diabetes mellitus is confirmed when all the following three findings are present:
  1\) Occurrence of diabetic ketosis or ketoacidosis soon (approximately 7 days) after the onset of hyperglycemic symptoms (elevation of urinary and/or serum ketone bodies at first visit)
  2\) Plasma glucose level ≥16.0 mmol/L (≥288 mg/dL) and glycated hemoglobin level \<8.7% (NGSP value)[a](#jdi12024-note-0005){ref-type="fn"} at first visit
  3\) Urinary C‐peptide excretion \<10 μg/day or fasting serum C‐peptide level \<0.3 ng/mL (\<0.10 nmol/L) and \<0.5 ng/mL (\<0.17 nmol/L) after intravenous glucagon (or after meal) load at onset
  Other findings in fulminant type 1 diabetes mellitus
  A\) Islet‐related autoantibodies, such as antibodies to glutamic acid decarboxylase, islet‐associated antigen 2 and insulin, are undetectable in general
  B\) Duration of the disease before the start of insulin treatment can be 1--2 weeks
  C\) Elevation of serum pancreatic enzyme levels (amylase, lipase or elastase‐1) is observed in 98% of the patients
  D\) Flu‐like symptoms (fever, upper respiratory symptoms, etc.) or gastrointestinal symptoms (upper abdominal pain, nausea and/or vomiting, etc.) precede the disease onset in 70% of patients
  E\) The disease can occur during pregnancy or just after delivery
  F\) Association with HLA *DRB1\*04:05‐DQB1\*04:01* is reported
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

This value is not applicable for patients with previously diagnosed glucose intolerance. HLA, human leukocyte antigen, NGSP, National Glycohemoglobin Standardization Program.
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In the new criteria, we have added a comment that, 'This value (HbA~1c~ \<8.7% in NGSP) is not applicable for patients with previously diagnosed glucose intolerance'. Shimada *et al*. reported that in 18 patients with previously diagnosed glucose intolerance who showed rapid onset of hyperglycemia suggestive of fulminant type 1 diabetes, the mean value of HbA~1c~ was 8.5% (JDS), and it was more than 8.5% (JDS) in five patients (27.8%; 8.5% \[JDS\] = 8.9% \[NGSP\])[20](#jdi12024-bib-0020){ref-type="ref"}. This finding suggests that the HbA~1c~ concentration is higher in patients with previously diagnosed glucose intolerance than in patients without it in cases of fulminant type 1 diabetes.

We also added a new comment in the new criteria: 'Association with human leukocyte antigen (HLA) *DRB1\*04:05‐DQB1\*04:01* is reported' as a related finding. Kawabata and Ikegami have published this association as a committee report[14](#jdi12024-bib-0014){ref-type="ref"}. Imagawa and Ikegami have also reported that *DRB1\*04:05‐DQB1\*04:01* was seen in 32.6% of 207 fulminant type 1 diabetic patients, and this prevalence was remarkably higher than that in healthy control subjects (14.2%), with an odds ratio of 2.9[17](#jdi12024-bib-0017){ref-type="ref"}.

In contrast, we concluded that it was not necessary to revise the cut‐off value for the serum and urine C‐peptide levels based on the data for the newly‐diagnosed cases submitted to the committee during the past 8 years (data not shown). We also did not revise the other part of the diagnostic criteria and 'Other findings in fulminant type 1 diabetes mellitus', except for the addition of class II HLA, because the other parts of the previous criteria are still reliable. We agreed, as part of the present committee, that the 'Criteria for screening of fulminant type 1 diabetes mellitus (2004)' is still effective to be used in the future.

Based on the new lines of evidence, we have revised the diagnostic criteria for fulminant type 1 diabetes and include it as 'Criteria for definite diagnosis of fulminant type 1 diabetes mellitus (2012)'. We hope that these criteria will be widely used in various clinical and experimental situations, and will contribute to achieving a better understanding of this clinical entity. As we mentioned in the first committee report[4](#jdi12024-bib-0004){ref-type="ref"}, fulminant type 1 diabetes, if disregarded or not diagnosed, directly results in the death of the patient. We hope that these new criteria will help save the lives of patients with this rapidly‐progressing type of diabetes
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[^3]: In 2012, the Japan Diabetes Society established the Committee of the Japan Diabetes Society on the Research of Fulminant and Acute‐onset Type 1 Diabetes Mellitus, which published a committee report in *J Jpn Diabetes Soc* 2012; **55**: 815--820 (in Japanese)[1](#jdi12024-bib-0001){ref-type="ref"}. This is the English version of that report
